Trial Search Results

Long-Term Follow-up Protocol

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Krystal Biotech, Inc.

Stanford Investigator(s):


Inclusion Criteria:

   - All adult and pediatric participants who received at least one gene therapy treatment
   in a previous Krystal Biotech, Inc. sponsored study, and have discontinued or
   completed the parent treatment protocol (which do not have the LTFU embedded into the
   parent protocol), as applicable.

   - Consent/Assent must be obtained by the participants (and, parental/legal
   representative, when applicable) prior to any study-related data being collected.

   - Participant is willing and able to adhere to the protocol requirements.

Exclusion Criteria:

   - Participants who enroll into a non-Krystal Biotech, Inc. interventional gene therapy
   clinical trial will be excluded from the study.

Ages Eligible for Study

6 Months - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sinem Bagci